2.11
-0.05(-2.31%)
Currency In USD
| Previous Close | 2.16 |
| Open | 2.14 |
| Day High | 2.2 |
| Day Low | 2.08 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.52 |
| Volume | 72,708 |
| Average Volume | 200,816 |
| Market Cap | 55.03M |
| PE | 5.7 |
| EPS | 0.37 |
| Moving Average 50 Days | 3.19 |
| Moving Average 200 Days | 3.37 |
| Change | -0.05 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $21.14 as of June 30, 2025 at a share price of $2.11. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $107.38 as of June 30, 2025 at a share price of $2.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio Participates in Nasdaq Amplify Spotlight Series
GlobeNewswire Inc.
10 hours ago
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
GlobeNewswire Inc.
Jun 24, 2025 12:45 PM GMT
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Ge
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
GlobeNewswire Inc.
Jun 18, 2025 11:00 AM GMT
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management rele